Sign in

    Stephen Brozak

    Research Analyst at WBB Securities

    Stephen Brozak is the Managing Partner and President of WBB Securities, specializing in sell-side equity research and investment banking for the healthcare, biotechnology, pharmaceuticals, and medical device sectors. He has covered leading life sciences companies and earned top analyst rankings from StarMine, Financial Times, and The Wall Street Journal, including #2 analyst in pharmaceuticals and Best on the Street for medical equipment, with over 25 years of industry experience and consistent research accuracy. Brozak began his Wall Street career at firms such as Salomon Brothers, Dean Witter, Cowen & Company, and Alex. Brown & Sons before co-founding WBB Securities in 2004, where he leads research and deal execution. He holds numerous FINRA securities licenses (3, 7, 8, 24, 63, 65, 79, 86, 87, and 99), and has been recognized as a thought leader in healthcare finance across multiple media and peer-reviewed journals.

    Stephen Brozak's questions to OMEROS (OMER) leadership

    Stephen Brozak's questions to OMEROS (OMER) leadership • Q1 2025

    Question

    Stephen Brozak inquired about the commercial launch preparations for narsoplimab, including the go-to-market strategy and patient access plans. He also asked for more detail on the TA-TMA patient population and the economic value proposition of narsoplimab, considering the high costs already associated with stem cell transplant patients.

    Answer

    Chief Commercial Officer Nadia Dac detailed the launch strategy, which focuses on the top 40-80 transplant centers responsible for the majority of allogeneic transplant volume. She noted proactive engagement from payers and highlighted the drug's potential for both inpatient and outpatient use. CEO Gregory Demopulos described TA-TMA as a sudden, unpredictable, and often fatal complication with no currently approved treatments. Nadia Dac added that narsoplimab's economic value is driven by preventing costly outcomes like organ failure and death, with its outpatient potential offering further cost savings.

    Ask Fintool Equity Research AI

    Stephen Brozak's questions to OMEROS (OMER) leadership • Q4 2024

    Question

    Stephen Brozak of Rodman & Renshaw asked for a detailed explanation of the company's confidence in its resubmitted Biologics License Application (BLA) for narsoplimab.

    Answer

    Chairman and CEO Gregory Demopulos and Chief Regulatory Officer Catherine Melfi responded. Dr. Demopulos emphasized that the statistical analysis plan was developed with FDA agreement and the results were "impressively strong," showing a more than threefold improvement in survival with a p-value of less than 0.00001. Ms. Melfi added that the package is solid due to strong FDA collaboration, a well-matched external control group, and robust statistical modeling that consistently showed positive results.

    Ask Fintool Equity Research AI

    Stephen Brozak's questions to OMEROS (OMER) leadership • Q3 2024

    Question

    Stephen Brozak of WBB Securities asked if it is reasonable to assume Omeros will be commercially selling narsoplimab in 2025, given the minor nature of the FDA's recent requests and the company's plan for a swift BLA resubmission.

    Answer

    Executive Gregory Demopulos confirmed that commercializing narsoplimab in 2025 is the company's hope and expectation, targeting the earlier part of the year. He explained that the FDA's request was limited to additional sensitivity analyses. Once Omeros receives alignment on the statistical analysis plan (SAP), their external consultants will run the analyses, enabling a quick resubmission of the Biologics License Application (BLA).

    Ask Fintool Equity Research AI

    Stephen Brozak's questions to LISATA THERAPEUTICS (LSTA) leadership

    Stephen Brozak's questions to LISATA THERAPEUTICS (LSTA) leadership • Q3 2024

    Question

    Inquired about the scientific rationale for exploring certepetide in endometriosis, the current standard of care for the condition, and the patient enrollment rates for the company's major clinical trials compared to typical rates.

    Answer

    Endometriosis is a target because it's a tumor-like disease with upregulated receptors needed for certepetide's mechanism, and the goal is to stop angiogenesis with an anti-VEGF agent. Current care involves pain management and surgery. Trial enrollment has been strong, with the ASCEND trial showing good rates and the BOLSTER trial's first-line cohort enrolling 6 months ahead of schedule, demonstrating high investigator and patient interest.

    Ask Fintool Equity Research AI